Trump administration to launch TrumpRx website to guide consumers to discounted drug prices

UNITED STATES — The Trump administration is set to unveil TrumpRx, a new government-backed website aimed at helping consumers access discounted prescription drugs. The announcement is scheduled for Thursday evening, 5 February, 2026.

White House press secretary Karoline Leavitt revealed the launch in a post on X, calling TrumpRx "a state of the art website for American consumers to purchase low cost prescription drugs."

Despite the phrasing, the website will not be a marketplace for purchasing medication directly. Instead, it will act as a guide, linking users to pharmaceutical manufacturers’ direct-to-consumer platforms.

President Donald Trump is expected to announce the launch alongside Dr Mehmet Oz, Administrator of the Centers for Medicare and Medicaid Services (CMS), and Joe Gebbia, Director of the National Design Studio.

Trump first teased the initiative in September 2025, tying it to a broader policy push to lower drug prices in the U.S. by aligning them with those in other developed nations. He stated in December that the site would deliver “massive discounts to all consumers.”

However, questions remain about the effectiveness and reach of these discounts. It is unclear whether prices available on manufacturers’ websites will consistently be more favourable than what insured consumers pay through employer-sponsored plans or public programmes such as Medicaid and Medicare.

The TrumpRx rollout follows several delays. The administration initially planned to launch the platform by the end of 2025. A revised timeline for late January 2026 was also missed without public explanation.

Dr Oz previously stated the site would allow users to compare prices before year-end. However, specific tools or mechanisms for comparison have not yet been detailed.

Over recent months, Trump has used public appearances to highlight his administration's pharmaceutical pricing agreements. These include arrangements with major drugmakers like Pfizer, Eli Lilly and Merck.

The agreements reportedly involve offering "most favoured nation" pricing—aligning U.S. prices with the lowest rates charged in other developed countries—for some Medicaid-covered drugs.

Some newly developed treatments from these companies will also reportedly launch at discounted rates for the wider consumer market, accessible through TrumpRx. However, the precise terms and extent of these discounts remain opaque.

The Trump administration has also utilised provisions from a 2022 law enabling Medicare to negotiate prices directly for certain high-cost prescription drugs. This programme has resulted in lowered prices for some Medicare beneficiaries, although the scale of these reductions has yet to be independently evaluated.

Drug pricing in the U.S. remains a complex landscape, affected by insurance design, patent protections, competition, and regulatory processes. Most Americans rely on insurance coverage to offset medication costs, which can vary significantly depending on a drug’s status, availability, and market competition.

The launch of TrumpRx represents the latest attempt to intervene in that landscape by increasing visibility and, potentially, access to more competitive pricing.

Whether it results in real savings for a wide range of consumers will likely depend on further implementation details and the responsiveness of pharmaceutical companies to the administration’s pricing framework.